Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Brickell, Vical reverse merge to create company focused on Brickell's dermatology pipeline

Executive Summary

Publicly traded infectious disease-focused biotech Vical Inc. and private spec pharma Brickell Biotech Inc. have agreed to reverse merge in an all-stock transaction, creating a combined company (owned 60% by Brickell/40% by Vical), which will take over Vical's NASDAQ listing under a new ticker symbol, operate under the Brickell Biotech name, and retain Brickell's current management team and corporate headquarters in Boulder, Colorado.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Acquisition of Private Biotech
    • Payment Includes Stock
    • Reverse Acquisition
    • Intra-Biotech Deal

Related Companies